So we have poor evidence of efficacy, small but significant increases in suicide risk, and significant, probably underestimated, adverse events. The evidence therefore shows us that antidepressants are not demonstrably 'better than nothing' and may be worse. This conclusion will be at odds with many general practitioners' clinical experience in using these that antidepressants are not appropriate for the treatment of mild depression in any age group. 9 Their proposed strategy of 'watchful waiting' is appropriate for children with mild-moderate depression. Where acute risk is low, a general practitioner might offer a brief explanation about depression, sleep hygiene, the usefulness of finding a confidante, the benefits of exercise and of gradually resuming any activities set aside because the individual is 'too depressed'. The general practitioner should then arrange to see the patient again in about two weeks but offer to talk to them earlier if they are worried.
In more severe cases, referral to or consultation with a child and adolescent mental health service or a child psychiatrist is recommended. The unavailability of such services is an indication for advocacy; it does not mandate prescribing against available evidence. Such prescribing, based on faith or hope that antidepressants may actually be better than the evidence indicates, risks contravening the injunction to 'first do no harm'. paroxetine.
(Aust Prescr 2005;28:xx)
Controlled trials show that psychosocial treatments such as cognitive behaviour therapy 1 and interpersonal psychotherapy are effective in mild to moderate paediatric depression.
However, effectiveness in severe depression (when symptoms are serious and last more than six weeks in at least two of three contexts -home, school, peers) is questionable. 2 This raises the question of drug treatment.
Tricyclic antidepressants are not more effective than placebo in children and adolescents. 3 showed that of all depressed adolescents, 11% had seen a GP or paediatrician, 17% had used mental health services, and only 3% had been prescribed antidepressants. 7 The current evidence suggests that psychosocial treatments, not medication, should be used in mild and moderate depression, but they are no panacea. 2 Delivering them can pose challenges because clinicians may lack skills and confidence in using these therapies. Psychosocial treatments may also be unavailable in public sector services or be difficult to access because of cost, long waiting lists, or lack of services (for example, in rural areas). Further, depressed young people may be more reluctant to become engaged in these treatments because of anger, lack of motivation or insight, and demoralisation. Fluoxetine has a place in the treatment of severe depression in the young. 2, 4 Fluoxetine and cognitive behaviour therapy should be the preferred option because the combination may be more effective and may reduce suicidal risk. 2 When treatment with SSRIs is begun, the patients (and their families when appropriate -for example in younger adolescents) must be informed of the risk of increased suicidal thoughts and attempts, and adverse effects, so that they can 
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Varicella vaccine
In 2000 mathematical modelling showed that immunising 90% of infants would produce an initial 'honeymoon' period of low incidence, one or more post-honeymoon epidemics in adolescents and young adults 10 to 20 years later, and an equilibrium reached after 20 to 40 years in which the incidence in adults is similar to that in the pre-vaccine years. 1 The evidence from the USA on reduced incidence in all age groups covers only five years of experience, which is within the honeymoon period predicted by the modelling. This is insufficient time for epidemics in adults to occur through the build-up of susceptible people, as partial population immunity increases the interepidemic interval.
The impact of varicella vaccine on herpes zoster is complex.
There is reasonable evidence that adults exposed to children, or exposed to chickenpox, have less chance of developing zoster, through presumed immunologic boosting by exposure to varicella zoster virus. 2 Modelling shows that immunisation causes an increase in herpes zoster for up to 50 years until immunised infants reach old age.
Due to the infectivity of reactivated herpes zoster it is not possible to eliminate varicella zoster virus in the way measles or polio could be eliminated completely. The aim of immunisation is therefore to reduce the burden of varicella disease rather than disease elimination. Since the burden of serious disease, particularly mortality, is in adults, and the modelling shows that in the long term the incidence in adults will not be affected by even high levels of vaccination coverage, the logic of universal vaccination has to be questioned.
Vaccination undoubtedly reduces childhood disease and saves the costs of medical care, childcare costs and lost income for parents while they look after sick children. Health decisions, however, should be primarily based on health considerations rather than economics.
The current low burden of disease from varicella means that it would take only a small rise in varicella in adults for us to be worse off than we were without the vaccine.
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